KR20190113083A - Analgesic Composition comprising layered metal hydroxide - Google Patents

Abstract

The present invention relates to an analgesic composition containing an anionic active component and a layered metal hydroxide. More specifically, the present invention relates to the analgesic composition containing a complex comprising a layered metal salt and the anionic active component as active components. An object of the present invention is to provide the analgesic composition comprising the complex comprising the layered metal salt and the anionic active ingredient as active components.

Description

Analgesic Composition comprising layered metal hydroxide

The present invention relates to an analgesic composition comprising a layered metal hydroxide, and more particularly to an analgesic composition comprising a complex comprising a layered metal salt and an anionic active ingredient as an active ingredient.

One object of the present invention is to provide an analgesic composition comprising a complex comprising a layered metal salt and an anionic active ingredient as an active ingredient.

In order to achieve the above object, one embodiment of the present invention provides an analgesic composition with a composite comprising a layered metal salt and an anionic active ingredient as an active ingredient.

As used herein, the term "layered metal salt" means a weakly basic or neutral inorganic compound. The crystal structure shows a specific interlayer reactivity as a layered type, and has anion exchange capacity, which can be effectively used for stabilizing anionic components.

Specifically, the layered metal salt may be a layered metal hydroxide, and in particular, the layered metal hydroxide may be metal double hydroxides (HDS) or layered double hydroxides (LDH), but is not limited thereto. It is not.

Anionic substances having an antioxidant capacity, for example, vitamin C, are inserted or formed in a mixture with the metal salts between the layers of the layered metal salts provided in the present invention.

In the present specification, the complex may be interchangeably referred to as 'hybrid'.

Specifically, the complex may be metal double hydroxides (HDS) or layered double hydroxides (LDH) represented by Formula 1 or Formula 2 below, and more specifically, zinc basic salts (Zinc basic). salts, ZBS; Zn ₅ (OH) ₈ Cl _{2 It} may have a crystal structure in the form of nH ₂ O), but is not limited thereto.

[Formula 1]

[M (IIII) (OH) ₂ ) ^{x +} ((A ^n- ) ^{x / y-} ] zH ₂ O

[Formula 2]

[(M (II) _(1-x) M (III) _x (OH) ₂ ) ^{x +} · [(A ^n- ) ^{x / y-} ] .zH ₂ O

In Formulas 1 and 2, M (II) is a divalent metal cation selected from the group consisting of Mg ²⁺ , Ni ²⁺ , Ca ²⁺ , Cu ²⁺ and Zn ²⁺ , and M (III) is Al ^{3 Is a} trivalent metal cation selected from the group consisting of ⁺ , Fe ³⁺ , V ³⁺ , Ti ³⁺ and Ga ³⁺ , x is a number ranging from 0.1 to 0.4, A is vitamin C, y is A Anion charge number, z is a positive number greater than zero.

In the present invention, the divalent metal cation and the trivalent metal cation are not limited to the above kind, and include all those known as layer metal salts in the art.

Meanwhile, the analgesic composition of the present invention may further include a suitable carrier, excipient, or diluent commonly used in the manufacture of a pharmaceutical composition, and the carrier may include a non-naturally occuring carrier.

Specific examples, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the compositions may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, oral formulations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. . As a specific example, the pharmaceutical composition may be a topical skin preparation, and more specifically, the topical skin preparation may be a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation It may be formulated to any one selected from the group including emulsion foundation, wax foundation, and spray, but is not limited to any formulation used in the art for application to the skin.

As used herein, the term " external preparation " refers to external preparations, external preparations, external preparations, ointments, warning agents, suppositories, and the like. The external preparation for skin of the present invention includes, without limitation, preparations that act on the external application of the skin, but may be an ointment in particular.

The external preparation for skin of the present invention may include conventionally acceptable ingredients in addition to the active ingredient, and may include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.

The external preparations of the present invention may be prepared in any formulations conventionally prepared in the art, including, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation, spray, and the like, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

Hereinafter, the present invention will be described in detail by way of examples. However, these examples are intended to illustrate the present invention in more detail, and the scope of the present invention is not limited to these examples.

As shown in FIG. 1, when a test substance mixed with a therapeutic drug and vitabrid C was applied to the atopy-induced mouse / steroid drug treatment group for 2 weeks, the histamine secretion was increased in the 30: 1 mixing ratio group. It was confirmed that the decrease.

Example 1 Synthesis of Layered Metal Hydroxide

50 g of Zn (NO ₃ ) ₂ .6H ₂ O was dissolved in a solution of 1.5L of purified water and 1.5L of ethanol from which carbonate ions (CO ₃ ^2- ) were removed, followed by stirring for 1 hour at room temperature and nitrogen. It was. The 1.6M NaOH aqueous solution was slowly added to a solution in which Zn (NO ₃ ) ₂ .6H ₂ O was dissolved to adjust the pH to 6-7, and stirred for 4 hours at room temperature and nitrogen. Over time, a precipitate was formed, and the suspension was separated from the precipitate and the filtrate using a centrifuge and washed three more times with 50% ethanol to remove impurities. The precipitate on the slurry obtained after washing was lyophilized to obtain fine particulate powder. The layered metal hydroxide of the obtained white powder was used for the experimental example of this invention as a sample.

Example 2 Synthesis of Vitamin C-Layered Metal Hydroxide Hybrids

Under normal temperature and nitrogen conditions, 48 g of vitamin C (Ascorbic acid, sigma) was dissolved in a solution of 70 mL of purified water without carbonate ions (CO ₃ ^2- ) and 630 mL of ethanol. 280 mL of an aqueous solution containing Zn (NO ₃ ) ₂ .6H ₂ O was added and stirred. 1.6M NaOH aqueous solution was slowly added to the above solution, the pH was adjusted to 6-7, and the mixture was stirred at room temperature and nitrogen for 6 hours. Over time, a precipitate was formed, and the suspension was separated from the precipitate and the filtrate by using a centrifuge, and the precipitate was washed three times or more with 50% ethanol to remove impurities. The precipitate on the slurry obtained after washing was lyophilized to obtain fine particulate powder. The vitamin C-layered metal hydroxide hybrid of the obtained white powder was named "hybrid" or "composite" in the present invention, and was used in the experimental example of the present invention.

Experimental Example 1. Confirmation of analgesic effect in animal model of vitamin C-layered metal hydroxide hybrid

The effect of the hybrid obtained through the above Example was confirmed as shown in FIG.

As shown in FIG. 1, when a test substance mixed with a therapeutic drug and vitabrid C was applied to the atopy-induced mouse / steroid drug treatment group for 2 weeks, the histamine secretion was increased in the 30: 1 mixing ratio group. It was confirmed that the decrease.

Claims (3)

An analgesic composition comprising a complex comprising a layered metal salt and an anionic active ingredient interposed therebetween as an active ingredient.
The analgesic composition of claim 1 wherein the anionic active ingredient is an antioxidant.
The analgesic composition according to claim 1, wherein the anionic active ingredient is vitamin C.

Images